StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.01−0.27 (-2.86%)

Close on Nov 18, 2026Market cap $579.84MP/E –Yield –

Cullinan Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Cullinan Therapeutics's revenue for the twelve months ending Dec 31, 2022 was $0, down 100.0% year over year. For fiscal 2022 it was $0, down 100.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$0-100.0%
FY2021Dec 31, 2021$18.94M–
FY2020Dec 31, 2020$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$0–
Q1 FY2022Mar 31, 2022$0-100.0%
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$0–
Q1 FY2021Mar 31, 2021$18.94M–

More Cullinan Therapeutics figures

See a number that looks wrong?